These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 19317892)

  • 1. Microbial factories for recombinant pharmaceuticals.
    Ferrer-Miralles N; Domingo-Espín J; Corchero JL; Vázquez E; Villaverde A
    Microb Cell Fact; 2009 Mar; 8():17. PubMed ID: 19317892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A.
    Unzueta U; Vázquez F; Accardi G; Mendoza R; Toledo-Rubio V; Giuliani M; Sannino F; Parrilli E; Abasolo I; Schwartz S; Tutino ML; Villaverde A; Corchero JL; Ferrer-Miralles N
    Appl Microbiol Biotechnol; 2015 Jul; 99(14):5863-74. PubMed ID: 25616525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting Escherichia coli as microbial factory for enhanced production of human serum albumin.
    Sharma A; Chaudhuri TK
    Microb Cell Fact; 2017 Oct; 16(1):173. PubMed ID: 28982367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escherichia coli in the production of biopharmaceuticals.
    İncir İ; Kaplan Ö
    Biotechnol Appl Biochem; 2024 Sep; ():. PubMed ID: 39245907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Yeasts as Hosts for Recombinant Protein Production.
    Vieira Gomes AM; Souza Carmo T; Silva Carvalho L; Mendonça Bahia F; Parachin NS
    Microorganisms; 2018 Apr; 6(2):. PubMed ID: 29710826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends.
    Kyriakopoulos S; Kontoravdi C
    Eur J Pharm Sci; 2013 Feb; 48(3):428-41. PubMed ID: 23262060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of pharmaceutical proteins by transgenic animals.
    Houdebine LM
    Comp Immunol Microbiol Infect Dis; 2009 Mar; 32(2):107-21. PubMed ID: 18243312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering microbial cell factories for the production of plant natural products: from design principles to industrial-scale production.
    Liu X; Ding W; Jiang H
    Microb Cell Fact; 2017 Jul; 16(1):125. PubMed ID: 28724386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant pharmaceuticals from microbial cells: a 2015 update.
    Sanchez-Garcia L; Martín L; Mangues R; Ferrer-Miralles N; Vázquez E; Villaverde A
    Microb Cell Fact; 2016 Feb; 15():33. PubMed ID: 26861699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yeast synthetic biology for the production of recombinant therapeutic proteins.
    Kim H; Yoo SJ; Kang HA
    FEMS Yeast Res; 2015 Feb; 15(1):1-16. PubMed ID: 25130199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yeast synthetic biology for designed cell factories producing secretory recombinant proteins.
    Thak EJ; Yoo SJ; Moon HY; Kang HA
    FEMS Yeast Res; 2020 Mar; 20(2):. PubMed ID: 32009173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of Terpenoids by Synthetic Biology Approaches.
    Zhang C; Hong K
    Front Bioeng Biotechnol; 2020; 8():347. PubMed ID: 32391346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial protein cell factories fight back?
    ;
    Trends Biotechnol; 2022 May; 40(5):576-590. PubMed ID: 34924209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant expression systems for allergen vaccines.
    Singh MB; Bhalla PL
    Inflamm Allergy Drug Targets; 2006 Jan; 5(1):53-9. PubMed ID: 16613564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant protein production in yeasts.
    Mattanovich D; Branduardi P; Dato L; Gasser B; Sauer M; Porro D
    Methods Mol Biol; 2012; 824():329-58. PubMed ID: 22160907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renaissance of yeasts as microbial factories in the modern age of biomanufacturing.
    Payen C; Thompson D
    Yeast; 2019 Dec; 36(12):685-700. PubMed ID: 31423599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human recombinant lysosomal enzymes produced in microorganisms.
    Espejo-Mojica ÁJ; Alméciga-Díaz CJ; Rodríguez A; Mosquera Á; Díaz D; Beltrán L; Díaz S; Pimentel N; Moreno J; Sánchez J; Sánchez OF; Córdoba H; Poutou-Piñales RA; Barrera LA
    Mol Genet Metab; 2015; 116(1-2):13-23. PubMed ID: 26071627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
    Corchero JL; Gasser B; Resina D; Smith W; Parrilli E; Vázquez F; Abasolo I; Giuliani M; Jäntti J; Ferrer P; Saloheimo M; Mattanovich D; Schwartz S; Tutino ML; Villaverde A
    Biotechnol Adv; 2013; 31(2):140-53. PubMed ID: 22985698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.